|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2000-8-8
|
|
pubmed:abstractText |
Based on preclinical data demonstrating synergy between camptothecin analogues and taxanes, we determined the maximum tolerated dose (MTD) of irinotecan that could be given in combination with a fixed dose of paclitaxel of 75 mg/m2, when both drugs were delivered on a weekly schedule. The pharmacokinetics of this combination were explored to determine whether the sequence of administration affected the elimination of irinotecan.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
43-50
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10912577-Aged,
pubmed-meshheading:10912577-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10912577-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10912577-Camptothecin,
pubmed-meshheading:10912577-Dose-Response Relationship, Drug,
pubmed-meshheading:10912577-Drug Administration Schedule,
pubmed-meshheading:10912577-Drug Resistance, Neoplasm,
pubmed-meshheading:10912577-Female,
pubmed-meshheading:10912577-Humans,
pubmed-meshheading:10912577-Male,
pubmed-meshheading:10912577-Middle Aged,
pubmed-meshheading:10912577-Neoplasms,
pubmed-meshheading:10912577-Paclitaxel
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
|
|
pubmed:affiliation |
Department of Medicine, Yale University School of Medicine and the Yale Cancer Center, New Haven, CT 06520, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
